Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)

2 weeks ago 10

Muhammad Ali Khalid

Mon, February 16, 2026 astatine 11:23 AM CST 2 min read

Centessa Pharmaceuticals (NASDAQ:CNTA) is 1 of the 17 biotechnology stocks with much than 50% upside.

On January 29, Danielle Brill from Truist Financial raised her terms people connected Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy standing to the stock. Her standing came aft Truist Financial updated its projections pursuing a thorough reassessment of the existent information regarding the orexin-2 receptor agonist class.

Zoetis (ZTS) Hits New 52-Week Low connected  Dismal Outlook

Zoetis (ZTS) Hits New 52-Week Low connected Dismal Outlook

M. A. Arkhipov/Shutterstock.com

On January 16, Biren Amin from Piper Sandler maintained an Overweight standing connected Centessa Pharmaceuticals (NASDAQ:CNTA). He forecasted a $38 terms people for the stock, which implied a 57% upside potential.

Amin highlighted 2 large catalysts expected this quarter. These see the planned initiation of Phase 3 trials for ORX750 crossed NT1, NT2, and IH, on with further findings from the CRYSTAL-1 Phase 2 study. The expert is optimistic astir idiopathic hypersomnia arsenic it whitethorn correspond a larger and perchance underappreciated marketplace opportunity.

Centessa Pharmaceuticals (NASDAQ:CNTA) is progressive successful the find and improvement of transformative medicines for neurological and neurodegenerative diseases. The institution operates nether an asset-centric Research and Development model, with a portfolio of subsidiaries that enactment specialized probe programs. These idiosyncratic programs are treated arsenic abstracted entities to guarantee highly efficient, data-driven decision-making.

While we admit the imaginable of CNTA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.

Read Entire Article